The outcome of litigation brought by Novartis AG against the German Federal Joint Committee could determine the agency's ability to beat down prices for drugs that are already on the market.

The Federal Joint Committee (G-BA) determines benefits covered by the country's statutory health insurance funds and specifies measures for quality assurance in patient care.